The API facility is designed to meet the global standards of the pharmaceutical industry. In Latvia, ursodeoxycholic acid manufacturer Grindeks has been certified to meet the ISO standards and the international GMP guidelines. The project created 35 new jobs at the UDCA unit. It has a total floor area of 2,300m2. The unit has powerful and modern technological devices to facilitate safe, convenient and efficient production. An automated management system is installed in the facility to regulate the production processes.

Ursodeoxycholic acid manufacturer use the energy-efficient system controls the microclimate in the work areas and facility premises, and provides working support to the engineering systems. It is expected to save significant amounts of energy.

Ursodeoxycholic acid manufacturer production: the output from the UDCA unit will be supplied to Marenis Pharma, a German pharmaceutical company. Grindeks made the initial pilot series delivery of UDCA production to Marenis Pharma in January 2008. A multistage, long-term supply agreement was signed between the two companies in 2009 after the quality assessment was found to be positive.

The UDCA facility will help Grindeks to maintain a continuous supply to Marenis Pharma.The company will supply about 30t of UDCA ingredients to Marenis Pharma in 2011. Grindeks expects to win 15% of the UDCA global market of 400t by 2014